|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||9.78 - 10.40|
|52-week range||3.60 - 25.77|
|Beta (3Y monthly)||2.07|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
DBV Technologies S.A. (EPA:DBV) shareholders should be happy to see the share price up 18% in the last month. But that...
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! DBV Technologies S.A. (EPA:DBV) is a stock Read More...
Biopharmaceutical firms Aimmune Therapeutics and DBV Technologies are both competing to develop drugs to treat peanut allergies and get FDA approval first in 2019.
In 2002 Pierre-Henri Benhamou was appointed CEO of DBV Technologies SA (EPA:DBV). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...